Nontuberculous Mycobacteria Market, By Drug Class, By Application, By Country, and By Region - Global Industry Analysis, Market Size, Market Share & Forecast from 2024-2032
Description
REPORT HIGHLIGHT
Nontuberculous Mycobacteria Market was valued at US$ 9,320.34 million by 2023, growing with 3.14% CAGR during the forecast period, 2024 2032.
Nontuberculous Mycobacteria (NTM) Market – Overview
Nontuberculous mycobacteria (NTM) infections are caused by environmental mycobacteria species found in water and soil, affecting primarily the lungs, skin, and soft tissues. These infections are distinct from tuberculosis and often require prolonged, combination-based antibiotic treatment due to their resistance patterns. The NTM market encompasses therapeutic drugs, supportive medications, and treatment regimens aimed at managing chronic infections, improving patient outcomes, and reducing recurrence rates.
Market Insights
The market is gaining attention due to increasing diagnosis rates, improved awareness among clinicians, and advancements in microbiological testing. NTM infections are often underdiagnosed, but the adoption of molecular diagnostics and culture-based identification is improving detection rates globally. Additionally, aging populations and the rising prevalence of chronic lung diseases are contributing to higher susceptibility. The market is also benefiting from ongoing research into targeted therapies and improved drug delivery mechanisms, particularly for pulmonary NTM infections.
Key Driver – Rising Prevalence of Chronic Respiratory Conditions
A major driver is the growing prevalence of underlying respiratory diseases that increase susceptibility to NTM infections. According to the World Health Organization, chronic respiratory diseases affect hundreds of millions of people globally, with conditions such as COPD and bronchiectasis significantly elevating the risk of NTM infections. As these patient populations expand, the incidence of NTM cases is also rising. This directly drives demand for long-term antibiotic therapies and supportive treatments, thereby strengthening the market growth trajectory.
Segment Insight – Drug Class (Oral Antibiotics)
Oral antibiotics account for a significant share in the NTM market due to their ease of administration and suitability for long-term outpatient treatment. Common regimens include macrolides, rifamycins, and ethambutol-based combinations, which are often prescribed over extended durations ranging from months to years. Oral therapies improve patient compliance compared to intravenous alternatives and are widely used in maintenance phases of treatment. Their accessibility and cost-effectiveness further support their dominant position in managing chronic NTM infections.
Competitive Insights
The market is moderately fragmented, with a mix of established pharmaceutical companies and specialty drug developers. Key players such as Pfizer Inc., Johnson & Johnson, Novartis AG, Teva Pharmaceutical Industries Ltd., and Insmed Incorporated hold notable positions in the market. Insmed is particularly prominent in NTM-focused therapies, while large pharmaceutical firms contribute through broad-spectrum antibiotics. Companies are focusing on inhaled and targeted therapies, clinical trials for novel antimicrobials, and regulatory approvals to strengthen their competitive positioning.
SCOPE OF THE REPORT
The scope of this report covers the market by its major segments, which include as follows:
GLOBAL NONTUBERCULOUS MYCOBACTERIA MARKET KEY PLAYERS- DETAILED COMPETITIVE INSIGHTS
Insmed
RedHill Biopharma Ltd
Novartis AG
Paratek Pharmaceuticals Inc
Janssen
RevImmune
Nobelpharma Co Ltd
Others
GLOBAL NONTUBERCULOUS MYCOBACTERIA MARKET, BY DRUG CLASS- MARKET ANALYSIS, 2019 - 2032
Oral Antibiotics
IV Antibiotics
Anti Nausea
Nebulized Antibiotics
Others
GLOBAL NONTUBERCULOUS MYCOBACTERIA MARKET, BY DISTRIBUTION CHANNEL- MARKET ANALYSIS, 2019 - 2032
Hospital pharmacies
Retail pharmacies
Online pharmacies
Others
GLOBAL NONTUBERCULOUS MYCOBACTERIA MARKET, BY REGION- MARKET ANALYSIS, 2019 - 2032
North America
U.S.
Canada
Europe
Germany
UK
France
Italy
Spain
The Netherlands
Sweden
Russia
Poland
Rest of Europe
Asia Pacific
China
India
Japan
South Korea
Australia
Indonesia
Thailand
Philippines
Rest of APAC
Latin America
Brazil
Mexico
Argentina
Colombia
Rest of LATAM
The Middle East and Africa
Saudi Arabia
UAE
Israel
Turkey
Algeria
Egypt
Rest of MEA
Nontuberculous Mycobacteria Market was valued at US$ 9,320.34 million by 2023, growing with 3.14% CAGR during the forecast period, 2024 2032.
Nontuberculous Mycobacteria (NTM) Market – Overview
Nontuberculous mycobacteria (NTM) infections are caused by environmental mycobacteria species found in water and soil, affecting primarily the lungs, skin, and soft tissues. These infections are distinct from tuberculosis and often require prolonged, combination-based antibiotic treatment due to their resistance patterns. The NTM market encompasses therapeutic drugs, supportive medications, and treatment regimens aimed at managing chronic infections, improving patient outcomes, and reducing recurrence rates.
Market Insights
The market is gaining attention due to increasing diagnosis rates, improved awareness among clinicians, and advancements in microbiological testing. NTM infections are often underdiagnosed, but the adoption of molecular diagnostics and culture-based identification is improving detection rates globally. Additionally, aging populations and the rising prevalence of chronic lung diseases are contributing to higher susceptibility. The market is also benefiting from ongoing research into targeted therapies and improved drug delivery mechanisms, particularly for pulmonary NTM infections.
Key Driver – Rising Prevalence of Chronic Respiratory Conditions
A major driver is the growing prevalence of underlying respiratory diseases that increase susceptibility to NTM infections. According to the World Health Organization, chronic respiratory diseases affect hundreds of millions of people globally, with conditions such as COPD and bronchiectasis significantly elevating the risk of NTM infections. As these patient populations expand, the incidence of NTM cases is also rising. This directly drives demand for long-term antibiotic therapies and supportive treatments, thereby strengthening the market growth trajectory.
Segment Insight – Drug Class (Oral Antibiotics)
Oral antibiotics account for a significant share in the NTM market due to their ease of administration and suitability for long-term outpatient treatment. Common regimens include macrolides, rifamycins, and ethambutol-based combinations, which are often prescribed over extended durations ranging from months to years. Oral therapies improve patient compliance compared to intravenous alternatives and are widely used in maintenance phases of treatment. Their accessibility and cost-effectiveness further support their dominant position in managing chronic NTM infections.
Competitive Insights
The market is moderately fragmented, with a mix of established pharmaceutical companies and specialty drug developers. Key players such as Pfizer Inc., Johnson & Johnson, Novartis AG, Teva Pharmaceutical Industries Ltd., and Insmed Incorporated hold notable positions in the market. Insmed is particularly prominent in NTM-focused therapies, while large pharmaceutical firms contribute through broad-spectrum antibiotics. Companies are focusing on inhaled and targeted therapies, clinical trials for novel antimicrobials, and regulatory approvals to strengthen their competitive positioning.
SCOPE OF THE REPORT
The scope of this report covers the market by its major segments, which include as follows:
GLOBAL NONTUBERCULOUS MYCOBACTERIA MARKET KEY PLAYERS- DETAILED COMPETITIVE INSIGHTS
Insmed
RedHill Biopharma Ltd
Novartis AG
Paratek Pharmaceuticals Inc
Janssen
RevImmune
Nobelpharma Co Ltd
Others
GLOBAL NONTUBERCULOUS MYCOBACTERIA MARKET, BY DRUG CLASS- MARKET ANALYSIS, 2019 - 2032
Oral Antibiotics
IV Antibiotics
Anti Nausea
Nebulized Antibiotics
Others
GLOBAL NONTUBERCULOUS MYCOBACTERIA MARKET, BY DISTRIBUTION CHANNEL- MARKET ANALYSIS, 2019 - 2032
Hospital pharmacies
Retail pharmacies
Online pharmacies
Others
GLOBAL NONTUBERCULOUS MYCOBACTERIA MARKET, BY REGION- MARKET ANALYSIS, 2019 - 2032
North America
U.S.
Canada
Europe
Germany
UK
France
Italy
Spain
The Netherlands
Sweden
Russia
Poland
Rest of Europe
Asia Pacific
China
India
Japan
South Korea
Australia
Indonesia
Thailand
Philippines
Rest of APAC
Latin America
Brazil
Mexico
Argentina
Colombia
Rest of LATAM
The Middle East and Africa
Saudi Arabia
UAE
Israel
Turkey
Algeria
Egypt
Rest of MEA
Table of Contents
376 Pages
- 1. Nontuberculous Mycobacteria Market Overview
- 1.1. Study Scope
- 1.2. Market Estimation Years
- 2. Executive Summary
- 2.1. Market Snippet
- 2.1.1. Nontuberculous Mycobacteria Market Snippet by Drug Class
- 2.1.2. Nontuberculous Mycobacteria Market Snippet by Distribution Channel
- 2.1.3. Nontuberculous Mycobacteria Market Snippet by Key Players
- 2.1.4. Nontuberculous Mycobacteria Market Snippet by Country
- 2.1.5. Nontuberculous Mycobacteria Market Snippet by Region
- 2.2. Competitive Insights
- 3. Nontuberculous Mycobacteria Key Market Trends
- 3.1. Nontuberculous Mycobacteria Market Drivers
- 3.1.1. Impact Analysis of Market Drivers
- 3.2. Nontuberculous Mycobacteria Market Restraints
- 3.2.1. Impact Analysis of Market Restraints
- 3.3. Nontuberculous Mycobacteria Market Opportunities
- 3.4. Nontuberculous Mycobacteria Market Future Trends
- 4. Nontuberculous Mycobacteria Industry Study
- 4.1. PEST Analysis
- 4.2. Porter’s Five Forces Analysis
- 4.3. Growth Prospect Mapping
- 4.4. Regulatory Framework Analysis
- 5. Nontuberculous Mycobacteria Market: Impact of Escalating Geopolitical Tensions
- 5.1. Impact of COVID-19 Pandemic
- 5.2. Impact of Russia-Ukraine War
- 5.3. Impact of Middle East Conflicts
- 6. Nontuberculous Mycobacteria Market Landscape
- 6.1. Nontuberculous Mycobacteria Market Share Analysis, 2024
- 6.2. Breakdown Data, by Key Manufacturer
- 6.2.1. Established Players’ Analysis
- 6.2.2. Emerging Players’ Analysis
- 7. Nontuberculous Mycobacteria Market – By Drug Class
- 7.1. Overview
- 7.1.1. Segment Share Analysis, By Drug Class, 2024 & 2032 (%)
- 7.1.2. Oral Antibiotics
- 7.1.3. IV Antibiotics
- 7.1.4. Anti Nausea
- 7.1.5. Nebulized Antibiotics
- 7.1.6. Others
- 8. Nontuberculous Mycobacteria Market – By Distribution Channel
- 8.1. Overview
- 8.1.1. Segment Share Analysis, By Distribution Channel, 2024 & 2032 (%)
- 8.1.2. Hospital pharmacies
- 8.1.3. Retail pharmacies
- 8.1.4. Online pharmacies
- 8.1.5. Others
- 9. Nontuberculous Mycobacteria Market– By Geography
- 9.1. Introduction
- 9.1.1. Segment Share Analysis, By Geography, 2024 & 2032 (%)
- 9.2. North America
- 9.2.1. Overview
- 9.2.2. Nontuberculous Mycobacteria Key Manufacturers in North America
- 9.2.3. North America Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
- 9.2.4. North America Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
- 9.2.5. North America Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
- 9.2.6. North America Market Size and Forecast, By Key Players, 2019 - 2032 (US$ Million)
- 9.2.7. U.S.
- 9.2.7.1. Overview
- 9.2.7.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
- 9.2.7.3. U.S. Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
- 9.2.7.4. U.S. Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
- 9.2.7.5. U.S. Market Size and Forecast, By Key Players, 2019 - 2032 (US$ Million)
- 9.2.8. Canada
- 9.2.8.1. Overview
- 9.2.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
- 9.2.8.3. Canada Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
- 9.2.8.4. Canada Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
- 9.2.8.5. Canada Market Size and Forecast, By Key Players, 2019 - 2032 (US$ Million)
- 9.3. Europe
- 9.3.1. Overview
- 9.3.2. Nontuberculous Mycobacteria Key Manufacturers in Europe
- 9.3.3. Europe Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
- 9.3.4. Europe Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
- 9.3.5. Europe Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
- 9.3.6. Europe Market Size and Forecast, By Key Players, 2019 - 2032 (US$ Million)
- 9.3.7. Germany
- 9.3.7.1. Overview
- 9.3.7.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
- 9.3.7.3. Germany Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
- 9.3.7.4. Germany Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
- 9.3.7.5. Germany Market Size and Forecast, By Key Players, 2019 - 2032 (US$ Million)
- 9.3.8. UK
- 9.3.8.1. Overview
- 9.3.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
- 9.3.8.3. UK Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
- 9.3.8.4. UK Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
- 9.3.8.5. UK Market Size and Forecast, By Key Players, 2019 - 2032 (US$ Million)
- 9.3.9. France
- 9.3.9.1. Overview
- 9.3.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
- 9.3.9.3. France Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
- 9.3.9.4. France Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
- 9.3.9.5. France Market Size and Forecast, By Key Players, 2019 - 2032 (US$ Million)
- 9.3.10. Italy
- 9.3.10.1. Overview
- 9.3.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
- 9.3.10.3. Italy Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
- 9.3.10.4. Italy Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
- 9.3.10.5. Italy Market Size and Forecast, By Key Players, 2019 - 2032 (US$ Million)
- 9.3.11. Spain
- 9.3.11.1. Overview
- 9.3.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
- 9.3.11.3. Spain Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
- 9.3.11.4. Spain Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
- 9.3.11.5. Spain Market Size and Forecast, By Key Players, 2019 - 2032 (US$ Million)
- 9.3.12. The Netherlands
- 9.3.12.1. Overview
- 9.3.12.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
- 9.3.12.3. The Netherlands Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
- 9.3.12.4. The Netherlands Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
- 9.3.12.5. The Netherlands Market Size and Forecast, By Key Players, 2019 - 2032 (US$ Million)
- 9.3.13. Sweden
- 9.3.13.1. Overview
- 9.3.13.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
- 9.3.13.3. Sweden Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
- 9.3.13.4. Sweden Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
- 9.3.13.5. Sweden Market Size and Forecast, By Key Players, 2019 - 2032 (US$ Million)
- 9.3.14. Russia
- 9.3.14.1. Overview
- 9.3.14.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
- 9.3.14.3. Russia Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
- 9.3.14.4. Russia Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
- 9.3.14.5. Russia Market Size and Forecast, By Key Players, 2019 - 2032 (US$ Million)
- 9.3.15. Poland
- 9.3.15.1. Overview
- 9.3.15.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
- 9.3.15.3. Poland Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
- 9.3.15.4. Poland Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
- 9.3.15.5. Poland Market Size and Forecast, By Key Players, 2019 - 2032 (US$ Million)
- 9.3.16. Rest of Europe
- 9.3.16.1. Overview
- 9.3.16.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
- 9.3.16.3. Rest of the Europe Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
- 9.3.16.4. Rest of the Europe Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
- 9.3.16.5. Rest of the Europe Market Size and Forecast, By Key Players, 2019 - 2032 (US$ Million)
- 9.4. Asia Pacific (APAC)
- 9.4.1. Overview
- 9.4.2. Nontuberculous Mycobacteria Key Manufacturers in Asia Pacific
- 9.4.3. APAC Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
- 9.4.4. APAC Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
- 9.4.5. APAC Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
- 9.4.6. APAC Market Size and Forecast, By Key Players, 2019 - 2032 (US$ Million)
- 9.4.7. China
- 9.4.7.1. Overview
- 9.4.7.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
- 9.4.7.3. China Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
- 9.4.7.4. China Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
- 9.4.7.5. China Market Size and Forecast, By Key Players, 2019 - 2032 (US$ Million)
- 9.4.8. India
- 9.4.8.1. Overview
- 9.4.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
- 9.4.8.3. India Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
- 9.4.8.4. India Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
- 9.4.8.5. India Market Size and Forecast, By Key Players, 2019 - 2032 (US$ Million)
- 9.4.9. Japan
- 9.4.9.1. Overview
- 9.4.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
- 9.4.9.3. Japan Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
- 9.4.9.4. Japan Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
- 9.4.9.5. Japan Market Size and Forecast, By Key Players, 2019 - 2032 (US$ Million)
- 9.4.10. South Korea
- 9.4.10.1. Overview
- 9.4.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
- 9.4.10.3. South Korea Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
- 9.4.10.4. South Korea Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
- 9.4.10.5. South Korea Market Size and Forecast, By Key Players, 2019 - 2032 (US$ Million)
- 9.4.11. Australia
- 9.4.11.1. Overview
- 9.4.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
- 9.4.11.3. Australia Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
- 9.4.11.4. Australia Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
- 9.4.11.5. Australia Market Size and Forecast, By Key Players, 2019 - 2032 (US$ Million)
- 9.4.12. Indonesia
- 9.4.12.1. Overview
- 9.4.12.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
- 9.4.12.3. Indonesia Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
- 9.4.12.4. Indonesia Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
- 9.4.12.5. Indonesia Market Size and Forecast, By Key Players, 2019 - 2032 (US$ Million)
- 9.4.13. Thailand
- 9.4.13.1. Overview
- 9.4.13.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
- 9.4.13.3. Thailand Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
- 9.4.13.4. Thailand Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
- 9.4.13.5. Thailand Market Size and Forecast, By Key Players, 2019 - 2032 (US$ Million)
- 9.4.14. Philippines
- 9.4.14.1. Overview
- 9.4.14.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
- 9.4.14.3. Philippines Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
- 9.4.14.4. Philippines Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
- 9.4.14.5. Philippines Market Size and Forecast, By Key Players, 2019 - 2032 (US$ Million)
- 9.4.15. Rest of APAC
- 9.4.15.1. Overview
- 9.4.15.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
- 9.4.15.3. Rest of APAC Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
- 9.4.15.4. Rest of APAC Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
- 9.4.15.5. Rest of APAC Market Size and Forecast, By Key Players, 2019 - 2032 (US$ Million)
- 9.5. Latin America (LATAM)
- 9.5.1. Overview
- 9.5.2. Nontuberculous Mycobacteria Key Manufacturers in Latin America
- 9.5.3. LATAM Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
- 9.5.4. LATAM Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
- 9.5.5. LATAM Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
- 9.5.6. LATAM Market Size and Forecast, By Key Players, 2019 - 2032 (US$ Million)
- 9.5.7. Brazil
- 9.5.7.1. Overview
- 9.5.7.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
- 9.5.7.3. Brazil Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
- 9.5.7.4. Brazil Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
- 9.5.7.5. Brazil Market Size and Forecast, By Key Players, 2019 - 2032 (US$ Million)
- 9.5.8. Mexico
- 9.5.8.1. Overview
- 9.5.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
- 9.5.8.3. Mexico Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
- 9.5.8.4. Mexico Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
- 9.5.8.5. Mexico Market Size and Forecast, By Key Players, 2019 - 2032 (US$ Million)
- 9.5.9. Argentina
- 9.5.9.1. Overview
- 9.5.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
- 9.5.9.3. Argentina Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
- 9.5.9.4. Argentina Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
- 9.5.9.5. Argentina Market Size and Forecast, By Key Players, 2019 - 2032 (US$ Million)
- 9.5.10. Colombia
- 9.5.10.1. Overview
- 9.5.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
- 9.5.10.3. Colombia Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
- 9.5.10.4. Colombia Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
- 9.5.10.5. Colombia Market Size and Forecast, By Key Players, 2019 - 2032 (US$ Million)
- 9.5.11. Rest of LATAM
- 9.5.11.1. Overview
- 9.5.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
- 9.5.11.3. Rest of LATAM Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
- 9.5.11.4. Rest of LATAM Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
- 9.5.11.5. Rest of LATAM Market Size and Forecast, By Key Players, 2019 - 2032 (US$ Million)
- 9.6. Middle East and Africa (MEA)
- 9.6.1. Overview
- 9.6.2. Nontuberculous Mycobacteria Key Manufacturers in Middle East and Africa
- 9.6.3. MEA Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
- 9.6.4. MEA Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
- 9.6.5. MEA Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
- 9.6.6. MEA Market Size and Forecast, By Key Players, 2019 - 2032 (US$ Million)
- 9.6.7. Saudi Arabia
- 9.6.7.1. Overview
- 9.6.7.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
- 9.6.7.3. Saudi Arabia Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
- 9.6.7.4. Saudi Arabia Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
- 9.6.7.5. Saudi Arabia Market Size and Forecast, By Key Players, 2019 - 2032 (US$ Million)
- 9.6.8. UAE
- 9.6.8.1. Overview
- 9.6.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
- 9.6.8.3. UAE Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
- 9.6.8.4. UAE Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
- 9.6.8.5. UAE Market Size and Forecast, By Key Players, 2019 - 2032 (US$ Million)
- 9.6.9. Israel
- 9.6.9.1. Overview
- 9.6.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
- 9.6.9.3. Israel Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
- 9.6.9.4. Israel Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
- 9.6.9.5. Israel Market Size and Forecast, By Key Players, 2019 - 2032 (US$ Million)
- 9.6.10. Turkey
- 9.6.10.1. Overview
- 9.6.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
- 9.6.10.3. Turkey Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
- 9.6.10.4. Turkey Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
- 9.6.10.5. Turkey Market Size and Forecast, By Key Players, 2019 - 2032 (US$ Million)
- 9.6.11. Algeria
- 9.6.11.1. Overview
- 9.6.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
- 9.6.11.3. Algeria Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
- 9.6.11.4. Algeria Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
- 9.6.11.5. Algeria Market Size and Forecast, By Key Players, 2019 - 2032 (US$ Million)
- 9.6.12. Egypt
- 9.6.12.1. Overview
- 9.6.12.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
- 9.6.12.3. Egypt Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
- 9.6.12.4. Egypt Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
- 9.6.12.5. Egypt Market Size and Forecast, By Key Players, 2019 - 2032 (US$ Million)
- 9.6.13. Rest of MEA
- 9.6.13.1. Overview
- 9.6.13.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
- 9.6.13.3. Rest of MEA Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
- 9.6.13.4. Rest of MEA Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
- 9.6.13.5. Rest of MEA Market Size and Forecast, By Key Players, 2019 - 2032 (US$ Million)
- 10. Key Vendor Analysis- Nontuberculous Mycobacteria Industry
- 10.1. Competitive Benchmarking
- 10.1.1. Competitive Dashboard
- 10.1.2. Competitive Positioning
- 10.2. Company Profiles
- 10.2.1. Insmed
- 10.2.2. RedHill Biopharma Ltd
- 10.2.3. Novartis AG
- 10.2.4. Paratek Pharmaceuticals Inc
- 10.2.5. Janssen
- 10.2.6. RevImmune
- 10.2.7. Nobelpharma Co Ltd
- 10.2.8. Others
- 11. 360 Degree AnalystView
- 12. Appendix
- 12.1. Research Methodology
- 12.2. References
- 12.3. Abbreviations
- 12.4. Disclaimer
- 12.5. Contact Us
Pricing
Currency Rates
Questions or Comments?
Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.
